Reducing hyperglycaemia linked to immune deficiency and viral proliferation, as well as glycaemic variability, considered a promoter of oxidative stress and consequent inflammation, GLP-1 Ra may represent a valuable treatment option for non-critically ill patients T2DM patients with COVID-19 [46]. Here, GLP1R is linked to Immunodeficiency.